832114-05-3

Usage

Uses

Used in Pharmaceutical Synthesis:
3-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID is used as a reagent for the synthesis of pharmaceuticals, leveraging its boronic acid functionality to form stable complexes with diols, which is essential in the development of new drugs with specific therapeutic properties.
Used in Agrochemical Development:
In the agrochemical industry, 3-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID is utilized as a key intermediate in the synthesis of various agrochemicals, contributing to the creation of effective compounds for pest control and crop protection.
Used in Material Science:
3-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID is employed as a component in the development of new materials, taking advantage of its ability to form stable complexes to enhance material properties or create novel material systems.
Used in Catalytic Processes:
As a reagent in catalytic processes, 3-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID is used to facilitate selective reactions, with the BOC group temporarily protecting the amine functionality, allowing for reactions to occur at other sites within the molecule, which is vital for the synthesis of complex organic molecules with specific functions.

InChI:InChI=1/C18H28BNO4/c1-16(2,3)22-15(21)20-12-13-9-8-10-14(11-13)19-23-17(4,5)18(6,7)24-19/h8-11H,12H2,1-7H3,(H,20,21)

Upstream product

• 10269-01-9 3-bromobenzylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73183-34-3 bis(pinacol)diborane 
• 171663-13-1 t-butyl N-(3-bromobenzyl)carbamate 

Downstream Products

• 1001414-51-2 tert-butyl 3-(4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzylcarbamate 

Relevant academic research and scientific papers

Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy

CARM1 is a protein arginine methyltransferase and acts as a transcriptional coactivator regulating multiple biological processes. Aberrant expression of CARM1 has been related to the progression of multiple types of cancers, and therefore CARM1 was consid

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF

Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.

Arginine methyltransferase inhibitor and pharmaceutical composition and application thereof

The invention relates to an arginine methyltransferase inhibitor and a pharmaceutical composition and application thereof, in particular to a compound represented by a formula (I), a pharmaceuticallyacceptable salt, isomer, racemate, prodrug, co-crystal c

CaMKII INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of Ca2+/calmodulindependent protein kinase (CaMKII), compositions thereof, and methods of using the same. Cardiovascular disease remains the number one cause of death in developed countries. Furthermore, incidence of cardiovascular disease has increased dramatically in developing countries. Although cardiovascular disease usually affects older adults, the antecedents of cardiovascular disease, notably atherosclerosis, begin in early life, making primary prevention efforts necessary from childhood.

PYRIDINONYL PDK1 INHIBITORS

The present invention provides pyridinonyl PDKl inhibitors and methods of treating cancer using the same.